摘要
目的探究不同手术方式联合新辅助化疗治疗非小细胞肺癌的临床疗效。方法收集2017年2月至2018年12月,在我院住院的早中期非小细胞肺癌患者86例,随机分为对照组和观察组,各43例。两组患者在GP化疗方案辅助化疗的基础上,观察组患者应用胸腔镜手术进行治疗,对照组患者应用传统开胸手术进行治疗,对比两组患者临床疗效。结果对照组与观察组在手术时间和淋巴结清扫数目上差异无统计学意义(P>0.05)。观察组在术中出血量、术后引流量、术后引流时间、住院时间以及VAS评分上均明显优于对照组(P<0.01)。对照组不良反应率高于观察组(P<0.05)。对照组与观察组在复发率和生存率并无明显差异(P>0.05)。结论胸腔镜联合新辅助化疗与传统开胸手术联合新辅助化疗治疗NSCLC相比,安全性、有效性、复发率和生存率无显著差异,但其具有创伤小、恢复快、不良反应率低等优点。值得推广应用。
Objective To explore the clinical efficacy of different surgical.Methods Combined with neoadjuvant chemotherapy in the treatment of non-small cell lung cancer.From February 2017 to July 2019,86 patients with early and mid-term non-small cell lung cancer hospitalized in our hospital were collected and randomly divided into a control group and an observation group,with 43 cases each.The two groups of patients were based on GP chemotherapy and adjuvant chemotherapy.Patients in the observation group were treated with thoracoscopic surgery,and patients in the control group were treated with traditional thoracotomy.The clinical efficacy of the two groups was compared.Results There was no significant difference in the operation time and the number of lymph node dissection between the control group and the observation group (P>0.05).The observation group was significantly better than the control group in terms of intraoperative blood loss,postoperative drainage volume,postoperative drainage time,hospital stay,and VAS score (P<0.01).The adverse reaction rate of the control group was higher than that of the observation group (P<0.05).There was no significant difference in relapse rate and survival rate between the control group and the observation group (P>0.05).Conclusion Compared with traditional thoracoscopic surgery combined with neoadjuvant chemotherapy in the treatment of NSCLC,thoracoscopic surgery combined with neoadjuvant chemotherapy has no significant difference in safety,effectiveness,recurrence rate and survival rate,but it has small trauma,fast recovery and low adverse reaction rate.It is worth promoting and applying.
作者
孙美娟
王凌凌
SUN Mei-juan;WANG Ling-ling(Oncology Department of Guan People's Hospital,Langfang,Hebei 065500;Hebei Petro China Central Hosital,Langfang,Hebei 065000)
出处
《智慧健康》
2021年第4期89-91,共3页
Smart Healthcare
关键词
非小细胞肺癌
电视胸腔镜手术
传统开胸手术
新辅助化疗
Non-small cell lung cancer
Video-assisted thoracoscopic surgery
Traditional thoracotomy
Neoadjuvant chemotherapy